Jeremy Veenstra-VanderWeele uses molecular and translational neuroscience research tools in the pursuit of new treatments for autism.
Jeremy Veenstra-VanderWeele
From this contributor
Why serotonin medications may yet help children with autism
A class of medications used to treat obsessive-compulsive disorder seems to ease compulsive behaviors in adults with autism. Why can't we tell if these medications work similarly in children with the condition?
Why serotonin medications may yet help children with autism
How to evaluate new medications for autism
There are no available medications for treating autism’s core symptoms, but there are several candidates in clinical trials. Jeremy Veenstra-VanderWeele describes the factors researchers must take into account when developing drugs for the disorder.
How to evaluate new medications for autism
Explore more from The Transmitter
Early experience reshapes zebrafish retinal cells, alters behavior
The cells undergo a classic form of plasticity previously thought to occur only in downstream visual circuits.
Early experience reshapes zebrafish retinal cells, alters behavior
The cells undergo a classic form of plasticity previously thought to occur only in downstream visual circuits.
Loss of interneuron plasticity may be shared hallmark of neurodevelopmental conditions
Restoring an experience-dependent interneuron plasticity gene in adulthood improves memory and cuts seizures in CNTNAP2 knockout mice, a new study shows.
Loss of interneuron plasticity may be shared hallmark of neurodevelopmental conditions
Restoring an experience-dependent interneuron plasticity gene in adulthood improves memory and cuts seizures in CNTNAP2 knockout mice, a new study shows.
Neuropsychiatric MRI brain signatures fail reproducibility test
Small neuroimaging studies are unlikely to capture consistent anatomical changes related to conditions such as autism, schizophrenia and mood disorders, according to a new “wake-up call” study.
Neuropsychiatric MRI brain signatures fail reproducibility test
Small neuroimaging studies are unlikely to capture consistent anatomical changes related to conditions such as autism, schizophrenia and mood disorders, according to a new “wake-up call” study.